Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women

dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.creatorBonduki, Claudio Emilio [UNIFESP]
dc.creatorLourenço, Dayse Maria [UNIFESP]
dc.creatorBaracat, Edmund Chada [UNIFESP]
dc.creatorHaidar, Mauro Abi [UNIFESP]
dc.creatorNoguti, Maria Aparecida Eiko [UNIFESP]
dc.creatorMotta, Eduardo Leme Alves da [UNIFESP]
dc.creatorLima, Geraldo Rodrigues de [UNIFESP]
dc.date.accessioned2016-01-24T12:30:33Z
dc.date.accessioned2023-09-04T18:32:43Z
dc.date.available2016-01-24T12:30:33Z
dc.date.available2023-09-04T18:32:43Z
dc.date.created2016-01-24T12:30:33Z
dc.date.issued1998-03-01
dc.identifierActa Obstetricia Et Gynecologica Scandinavica. Copenhagen: Munksgaard Int Publ Ltd, v. 77, n. 3, p. 330-333, 1998.
dc.identifier0001-6349
dc.identifierhttps://repositorio.unifesp.br/handle/11600/25876
dc.identifier10.1034/j.1600-0412.1998.770315.x
dc.identifierWOS:000072713400015
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8615976
dc.description.abstractBackground. This study was performed to evaluate antithrombin III levels in postmenopausal women receiving hormonal replacement treatment.Methods. It is a prospective randomized study concerning 19 postmenopausal patients, aged 40 to 65 years, who received either continuous daily oral equine conjugated estrogen 0.625 mg (group A, N=10) or daily transdermal 17 beta-estradiol 50 mu g (group B, N=9). Medroxyprogesterone acetate (5 mg/day, 14 days monthly) was given to all patients. Blood samples were obtained before and after 3, 6, 9 and 12 months of treatment. Coagulation tests included Antithrombin III (functional method), prothrombin time, partial activated prothrombin time, thrombin time, factor V, fibrinogen, platelet count and euglobulin lysis time. Friedman analysis of variance and Mann-Whitney test were used for statistical analysis.Results. Antithrombin III level was reduced (p<0.05) in group A but not in group B, although it remained within normal range. No changes were detected in the other coagulation tests.Conclusions. These data suggest that oral conjugated estrogen replacement reduces functional ATIII, whereas transdermal estradiol replacement therapy does not modify it.
dc.languageeng
dc.publisherMunksgaard Int Publ Ltd
dc.relationActa Obstetricia Et Gynecologica Scandinavica
dc.rightsAcesso restrito
dc.subjectAntithrombin III
dc.subjectEstrogen
dc.subjectHormonal replacement
dc.subjectMenopause
dc.subjectThromboembolism
dc.titleEffect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women
dc.typeArtigo


Este ítem pertenece a la siguiente institución